COMMUNIQUÉS West-GlobeNewswire

Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
04/11/2026
- Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + [...]
Kane Announces Publication of Real-World Evidence in the International Wound Journal
04/11/2026
Study reports improvements across multiple wound-healing outcomes associated with adjunctive use of revyve® Antimicrobial Wound Gel WINNIPEG, Manitoba, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ( [...]
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
04/11/2026
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study design; U.S. [...]
Biodesix to Participate in Upcoming Investor Conferences
04/11/2026
LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present at two upcoming [...]
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
04/11/2026
Tokyo, Japan and Cambridge, UK, 4 November 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) today announces that it has revised its consolidated financial forecast for the year ending 31 December 2026, [...]
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
04/11/2026
Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties. NXE0033744, an investigational oral EP4 receptor agonist [...]
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
04/11/2026
Partnership provides opportunities to further expand Boehringer Ingelheim’s portfolio of antibody-drug conjugates (ADCs) and T-cell engagers (TcEs) Agreement reinforces Boehringer Ingelheim’s long-term commitment to [...]
Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
04/11/2026
4 November - Financial report for the period 1 January 2026 to 30 September 2026 Financial performance Q3 2026 adjusted and reported sales increased by 4% at CER, driven by continued GLP-1 volume growth across the US [...]
German hospital introduces miscarriage care device
04/11/2026
New device offers dignified support for early pregnancy loss HAMBURG, Nov. 04, 2026 (GLOBE NEWSWIRE) -- A HOSPITAL in northern Germany has become the first in mainland Europe to offer an innovative medical device [...]
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
04/11/2026
The FDA recognizes through this designation both the clinical evidence supporting daridorexant and the significant unmet medical need in pediatric insomnia, where no FDA-approved pharmacological treatments are currently [...]
Eliminating Static Without Electricity - MEC Industries Introduces the Powerless ECO Ionizer
04/11/2026
Powerless ECO Ionizer Eliminates Static Without Electricity SEOUL, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MEC Industries introduces the Powerless ECO Ionizer , a static-control device that operates without an [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Pennant Announces Third Quarter 2026 Earnings Release and Call
04/11/2026
EAGLE, Idaho, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it [...]
ElderVoice Reports Its AI Phone Companion Alerted a Daughter After Her Mother Said She Was Panicking
04/11/2026
ElderVoice calls older adults on the phone they already own and texts their family when a call raises a serious worry. Early families say their parents feel less alone. Austin, TX, Nov. 03, 2026 (GLOBE NEWSWIRE) -- A 76 [...]
VitalHub Announces Q3 2026 Conference Call Date
03/11/2026
TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") announced today that it will release financial results for the third quarter 2026 ended September 30, 2026 [...]
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
03/11/2026
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2026
SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
03/11/2026
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Elevar Therapeutics Announces Lirafugratinib (Lyrfigtu) Added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as Second-line Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
03/11/2026
FORT LEE, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and [...]

Pages